{"protocolSection":{"identificationModule":{"nctId":"NCT06477419","orgStudyIdInfo":{"id":"24-081"},"organization":{"fullName":"Memorial Sloan Kettering Cancer Center","class":"OTHER"},"briefTitle":"A Study of Sacituzumab Govitecan in People With Mesothelioma","officialTitle":"Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Diffuse Pleural Mesothelioma"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2029-06-21","type":"ESTIMATED"},"completionDateStruct":{"date":"2029-06-21","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-21","studyFirstSubmitQcDate":"2024-06-21","studyFirstPostDateStruct":{"date":"2024-06-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-21","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Memorial Sloan Kettering Cancer Center","class":"OTHER"},"collaborators":[{"name":"Gilead Sciences","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment."},"conditionsModule":{"conditions":["Mesothelioma","Mesotheliomas Pleural","Mesothelioma; Pleura"],"keywords":["Mesothelioma","Mesotheliomas Pleural","Mesothelioma; Pleura","Diffuse Pleural Mesothelioma","Sacituzumab","24-081","Memorial Sloan Kettering Cancer Center"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":33,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Participants with Mesothelioma","type":"EXPERIMENTAL","description":"Participants will have pathologically confirmed diffuse pleural mesothelioma","interventionNames":["Drug: Sacituzumab govitecan-hziy"]}],"interventions":[{"type":"DRUG","name":"Sacituzumab govitecan-hziy","description":"After enrollment, participants will receive SG until disease progression or intolerable toxicity.","armGroupLabels":["Participants with Mesothelioma"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate","description":"Clinical efficacy of Sacituzumab Govitecan/SG determined by overall response rate by modified (m)RECIST criteria v1.1. Overall response rate defined as participants who achieve complete response or partial response as best overall response by modified RECIST criteria for mesothelioma","timeFrame":"2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial\n* Patient age ≥ 18 at time of consent\n* Pathologically confirmed diffuse pleural mesothelioma\n* Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)\n* Measurable disease by modified RECIST criteria for mesothelioma\n* Adequate tumor tissue (fresh or archival) available from standard of care biopsy for correlative analyses (defined as at least 12 unstained slides or 1 core unless otherwise approved by the study PI)\n* Karnofsky Performance Status ≥ 70%\n* Adequate organ function, defined as\n\n  * Absolute neutrophil count ≥ 1.5K/mcL\n  * Platelet count ≥ 100K/mcL\n  * Adequate renal function defined as creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula)\n  * Hemoglobin \\> 8g/dL (prior transfusion permitted if not within 7 days of enrollment)\n  * Total bilirubin ≤1.5 x upper limit of normal (ULN) if no liver metastases or \\<3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits\n  * AST, ALT ≤ 3 x ULN (if liver metastases are present, ≤5 × ULN)\n* If of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapy\n\nExclusion Criteria:\n\n* Currently participating in another study and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment\n* Prior hypersensitivity to irinotecan or any components of sacituzumab govitecan-hziy\n* Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1 or has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; excluding irreversible AEs such as hypothyroidism) from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)\n* Known psychiatric or substance abuse disorders that would interfere with the requirements of the trial within the opinion of the investigator\n* Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early stage prostate cancer, or in situ cervical cancer after definitive treatment\n* Positive hepatitis B (hepatitis B virus \\[HBV\\]) surface antigen (HBsAg)\n\n  o NOTE: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Patients who fit these criteria must use Hep B prophylaxis during treatment. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing\n* Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:\n\n  * Receiving ART that may interfere with study treatment (consult sponsor for review of medication prior to enrollment)\n  * CD4 count \\< 350 cells/mm3 at screening\n  * AIDS-defining opportunistic infection within 6 months of start of screening\n  * Not agreeing to start ART and be on ART \\> 4 weeks plus having HIV viral load \\<400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled)\n* Pregnant women or women who are breastfeeding or of childbearing potential and not using a highly effective method of birth control for at least one month prior to enrollment. If the risk of contraception exists, male and female subjects must use highly effective contraception throughout the study and for at least 60 days after last treatment. Highly effective contraception includes either 2 barrier methods (diaphragm, condom by the partner, copper intrauterine device, sponge, or spermicide), or 1 barrier method and 1 hormonal method (any oral, subcutaneous, intrauterine, or intramuscular registered and marketed contraceptive agent that contains an estrogen and/or a progesterone agent)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-608-3763","email":"offinm@mskcc.org"},{"name":"Robert Daly, MD, MBA","role":"CONTACT","phone":"646-608-3789","email":"dalyr1@mskcc.org"}],"overallOfficials":[{"name":"Michael Offin, MD","affiliation":"Memorial Sloan Kettering Cancer Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Memorial Sloan Kettering Basking Ridge","status":"RECRUITING","city":"Basking Ridge","state":"New Jersey","zip":"07920","country":"United States","contacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-449-1778"}],"geoPoint":{"lat":40.70621,"lon":-74.54932}},{"facility":"Memorial Sloan Kettering Monmouth","status":"RECRUITING","city":"Middletown","state":"New Jersey","zip":"07748","country":"United States","contacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-608-3763"}],"geoPoint":{"lat":40.39652,"lon":-74.09211}},{"facility":"Memorial Sloan Kettering Bergen","status":"RECRUITING","city":"Montvale","state":"New Jersey","zip":"07645","country":"United States","contacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-608-3763"}],"geoPoint":{"lat":41.04676,"lon":-74.02292}},{"facility":"Memorial Sloan Kettering Cancer Center @ Commack","status":"RECRUITING","city":"Commack","state":"New York","zip":"11725","country":"United States","contacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-608-3763"}],"geoPoint":{"lat":40.84288,"lon":-73.29289}},{"facility":"Memorial Sloan Kettering Westchester","status":"RECRUITING","city":"Harrison","state":"New York","zip":"10604","country":"United States","contacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-608-3763"}],"geoPoint":{"lat":40.96899,"lon":-73.71263}},{"facility":"Memorial Sloan - Kettering Cancer Center","status":"RECRUITING","city":"New York","state":"New York","zip":"10021","country":"United States","contacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-608-3763"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Memorial Sloan Kettering Nassau","status":"RECRUITING","city":"Uniondale","state":"New York","zip":"11553","country":"United States","contacts":[{"name":"Michael Offin, MD","role":"CONTACT","phone":"646-608-3763"}],"geoPoint":{"lat":40.70038,"lon":-73.59291}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Memorial Sloan Kettering Cancer Center","url":"http://www.mskcc.org"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000008654","term":"Mesothelioma"},{"id":"D000086002","term":"Mesothelioma, Malignant"}],"ancestors":[{"id":"D000000236","term":"Adenoma"},{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000018301","term":"Neoplasms, Mesothelial"},{"id":"D000008175","term":"Lung Neoplasms"},{"id":"D000012142","term":"Respiratory Tract Neoplasms"},{"id":"D000013899","term":"Thoracic Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000010997","term":"Pleural Neoplasms"},{"id":"D000008171","term":"Lung Diseases"},{"id":"D000012140","term":"Respiratory Tract Diseases"}],"browseLeaves":[{"id":"M11634","name":"Mesothelioma","asFound":"Mesothelioma","relevance":"HIGH"},{"id":"M2537","name":"Mesothelioma, Malignant","asFound":"Mesothelioma","relevance":"HIGH"},{"id":"M3591","name":"Adenoma","relevance":"LOW"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M20445","name":"Neoplasms, Mesothelial","relevance":"LOW"},{"id":"M11172","name":"Lung Neoplasms","relevance":"LOW"},{"id":"M14979","name":"Respiratory Tract Neoplasms","relevance":"LOW"},{"id":"M16658","name":"Thoracic Neoplasms","relevance":"LOW"},{"id":"M13887","name":"Pleural Neoplasms","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"T3584","name":"Malignant Mesothelioma","asFound":"Mesothelioma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000608132","term":"Sacituzumab govitecan"}],"ancestors":[{"id":"D000018796","term":"Immunoconjugates"},{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M287620","name":"Sacituzumab govitecan","asFound":"Triamcinolone acetonide","relevance":"HIGH"},{"id":"M20855","name":"Immunoconjugates","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}